Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. [electronic resource]
Producer: 20200831Description: e00058 p. digitalISSN:- 2155-384X
- Aged
- Antigens, CD -- drug effects
- CD4-Positive T-Lymphocytes -- drug effects
- CD8-Positive T-Lymphocytes -- drug effects
- Carcinoma, Hepatocellular -- drug therapy
- Disease Progression
- Female
- Hepatitis A Virus Cellular Receptor 2 -- drug effects
- Humans
- Immunotherapy -- methods
- Liver Neoplasms -- pathology
- Male
- Neoplasm Staging -- methods
- Predictive Value of Tests
- Prognosis
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Protein Kinase Inhibitors -- therapeutic use
- Sorafenib -- therapeutic use
- Up-Regulation
- Lymphocyte Activation Gene 3 Protein
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.